Epiroprim

Drug Profile

Epiroprim

Alternative Names: RO 118958

Latest Information Update: 14 Nov 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Roche
  • Class Antibacterials; Antiprotozoals; Diaminopyrimidines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections; Pneumocystis pneumonia; Toxoplasmosis

Most Recent Events

  • 06 Sep 2000 No-Development-Reported for Pneumocystis pneumonia in Switzerland (Unknown route)
  • 06 Sep 2000 No-Development-Reported for Toxoplasmosis in Switzerland (Unknown route)
  • 24 Jul 1995 Phase-I clinical trials for Pneumocystis pneumonia in Switzerland (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top